CAR T Cells for Refractory B Cell Malignancy

Inclusion Criteria: 1. The treat history meeting the following criteria: * Recurrence of lymphoma patients with imaging (CT/MRI/PET-CT) detection and pathological diagnosis, or recurrence including bone marrow morphology relapse and the MRD recurrence of myeloma patients or leukemia patients, after chemotherapy or stem cell transplantation; * Can't get complete remission (including MRD positive) after more than twice repeated chemotherapy of incipient lymphoma, myeloma or leukemia patients; * One or twice chemotherapy cannot get remission again (including MRD positive), but not suitable for chemotherapy of incipient lymphoma, myeloma or leukemia patients. 2. There is a measurable lesions before treatment at least; 3. ECOG score≤2; 4. To be aged 1 to 70 years; 5. More than a month lifetime from the consent signing date Exclusion Criteria: * Serious cardiac insufficiency, left ventricular ejection fraction\<50; * Has a history of severe pulmonary function damaging; * Merging other malignant tumor; * Merging uncontrolled infection; * Merging the metabolic diseases (except diabetes); * Merging severe autoimmune diseases or immunodeficiency disease; * patients with active hepatitis B or hepatitis C; * patients with HIV infection; * Has a history of serious allergies on Biological products (including antibiotics); * Happened in 3 \~ 4 acute GvHD after allogeneic hematopoietic stem cell transplantation on recurring patients Pregnancy or lactation women; Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.